BioAtla, Inc. (BCAB)
| Market Cap | 1.22B |
| Revenue (ttm) | 400,000 |
| Net Income (ttm) | n/a |
| Shares Out | 32.32M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,310,762 |
| Open | 36.56 |
| Previous Close | 36.67 |
| Day's Range | 34.51 - 37.10 |
| 52-Week Range | 27.15 - 76.63 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 76.25 (+120.7%) |
| Est. Earnings Date | Nov 12, 2021 |
About BCAB
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, h...
Financial Performance
In 2020, BioAtla's revenue was $429,000, a decrease of -91.75% compared to the previous year's $5.20 million. Losses were -$35.85 million, 20.3% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 76.25, which is an increase of 120.69% from the latest price.
News
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...
BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update
SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutic...
BioAtla to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announ...
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additi...
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...
BioAtla Announces Pricing of Initial Public Offering
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...
IPO Preview: BioAtla Begins $100 Million IPO Effort
San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'
Solid tumor biotech BioAtla files for a $100 million IPO
BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
BioAtla IPO Registration Document (S-1)
BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).